Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 16,811,878
  • Shares Outstanding, K 597,437
  • Annual Sales, $ 2,355 M
  • Annual Income, $ 1,135 M
  • 60-Month Beta 0.46
  • Price/Sales 7.19
  • Price/Cash Flow 6.20
  • Price/Book 1.72
Trade RPRX with:

Options Overview Details

View History
  • Implied Volatility 15.31% ( -25.40%)
  • Historical Volatility 20.30%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 58.59% on 06/13/24
  • IV Low 15.31% on 07/19/24
  • Put/Call Vol Ratio 0.02
  • Today's Volume 184
  • Volume Avg (30-Day) 160
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 10,374
  • Open Int (30-Day) 9,720

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate 0.95
  • Number of Estimates 3
  • High Estimate 0.98
  • Low Estimate 0.92
  • Prior Year 0.85
  • Growth Rate Est. (year over year) +11.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.20 +11.67%
on 07/09/24
28.73 -2.05%
on 07/18/24
+1.88 (+7.16%)
since 06/18/24
3-Month
25.20 +11.67%
on 07/09/24
28.99 -2.93%
on 05/02/24
-0.02 (-0.07%)
since 04/19/24
52-Week
25.20 +11.67%
on 07/09/24
31.66 -11.10%
on 02/27/24
-2.92 (-9.40%)
since 07/19/23

Most Recent Stories

More News
Wall Street Thinks These 3 Stocks Are Hidden Gems That Could Soar 43% to 59% Over the Next 12 Months

Analysts are quite bullish about these beaten-down stocks.

SLB : 49.67 (+1.95%)
BABA : 75.27 (-1.66%)
RPRX : 28.14 (-0.67%)
Why PTC Therapeutics Soared 15% Higher Today

The company scored a $1 billion upfront payment for expanding a commercial partnership.

PTCT : 32.63 (-0.55%)
RPRX : 28.14 (-0.67%)
2 Dividend Stocks Wall Street Thinks Can Rise by 50%

These stocks could give investors the best of both worlds: dividend income and the potential to earn a great profit.

RPRX : 28.14 (-0.67%)
JD : 26.26 (-0.08%)
PureTech Health and Royalty Pharma Enter into KarXT Royalty Agreement for up to $500 Million

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases, and Royalty...

PRTC : 22.10 (-1.78%)
PRTC.LN : 169.400 (+1.80%)
RPRX : 28.14 (-0.67%)
Ionis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readiness

/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma has acquired an interest...

IONS : 47.82 (+1.04%)
RPRX : 28.14 (-0.67%)
Arrowhead Pharmaceuticals Announces $25 Million Milestone Payment from Amgen

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced a $25M milestone payment from Amgen (NASDAQ: AMGN). This milestone was triggered by the first subject enrolled in Amgen’s Phase 3 trial of...

ARWR : 28.30 (+2.39%)
AMGN : 331.29 (+0.10%)
RPRX : 28.14 (-0.67%)
6 Stocks Warren Buffett Completely Exited in 2022

Despite being an active buyer this year, Buffett's company Berkshire Hathaway also sold several of its holdings as it repositioned its portfolio.

BRK.AX : 0.012 (unch)
BRK.A : 652,040.00 (-1.63%)
BRK.B : 434.47 (-1.66%)
BRK-A : N/A (N/A)
BRK-B : N/A (N/A)
VZ : 41.62 (-1.07%)
STOR : 32.21 (unch)
ABBV : 172.32 (+0.69%)
RPRX : 28.14 (-0.67%)
BMY : 42.64 (+0.59%)
WFC : 59.23 (-0.02%)
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Royalty Pharma plc (Nasdaq: RPRX) today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead for $250 million...

ARWR : 28.30 (+2.39%)
RPRX : 28.14 (-0.67%)
Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer

Reported another record quarter of YUPELRI® (revefenacin) net sales and profitability: $18.7 million Q3 2022 sales up 35% from Q3 2021 (TBPH implied 35%...

RPRX : 28.14 (-0.67%)
TBPH : 9.57 (-1.14%)
If You Own These 3 Growth Stocks, You Might Want to Rethink Your Position

There may be more trouble on the horizon for these stocks than most investors are seeing right now.

DE : 378.06 (-0.68%)
RPRX : 28.14 (-0.67%)
ERIE : 377.34 (-1.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko...

See More

Key Turning Points

3rd Resistance Point 28.83
2nd Resistance Point 28.65
1st Resistance Point 28.40
Last Price 28.14
1st Support Level 27.97
2nd Support Level 27.79
3rd Support Level 27.54

See More

52-Week High 31.66
Fibonacci 61.8% 29.19
Fibonacci 50% 28.43
Last Price 28.14
Fibonacci 38.2% 27.67
52-Week Low 25.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar